Palvella director granted 3,000 stock options

PALVELLA THERAPEUTICS director Christopher P. Kiritsy received a grant of stock options covering 3,000 shares of common stock at an exercise price of $102.19 per share.

Rhea-AI Filing Summary

PALVELLA THERAPEUTICS director Christopher P. Kiritsy received a grant of stock options covering 3,000 shares of common stock at an exercise price of $102.19 per share. These options expire on June 10, 2036 and vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service.

Insider Trade Summary

Grant/Award: 3,000 shares

Grant/Award 1 txn

Insider KIRITSY CHRISTOPHER P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 3,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option shares granted: 3,000 shares Exercise price: $102.19 per share Underlying shares: 3,000 shares +3 more

6 metrics

Option shares granted 3,000 shares Stock Option (Right to Buy) grant to director

Exercise price $102.19 per share Conversion/exercise price of stock options

Underlying shares 3,000 shares Common stock underlying the options

Post-grant option holdings 3,000 options Total options held after transaction

Expiration date June 10, 2036 Option term end date

Vesting condition Earlier of 1-year or next annual meeting Subject to continued service through vesting date

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 102.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) director Christopher P. Kiritsy report on this Form 4?

Christopher P. Kiritsy reported receiving a grant of stock options for 3,000 shares of Palvella Therapeutics common stock. The filing reflects a compensation-related award rather than an open-market stock purchase or sale.

How many Palvella Therapeutics (PVLA) shares are covered by the new stock options?

The new stock option grant covers 3,000 shares of common stock. Each option represents the right to buy one share, giving Kiritsy potential future ownership if he chooses to exercise the options.

What is the exercise price of Christopher P. Kiritsy’s Palvella (PVLA) stock options?

The options have an exercise price of $102.19 per share. This is the price Kiritsy would pay to purchase each underlying share if he exercises the stock options in the future.

When do Christopher P. Kiritsy’s Palvella Therapeutics (PVLA) stock options vest?

The options vest on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on Kiritsy’s continued service through the applicable vesting date.

When do the newly granted Palvella (PVLA) stock options expire?

The stock options granted to Christopher P. Kiritsy expire on June 10, 2036. After that expiration date, any unexercised options will no longer be exercisable for Palvella Therapeutics common stock.

How many Palvella (PVLA) options does Christopher P. Kiritsy hold after this grant?

Following this grant, Kiritsy holds 3,000 stock options according to the filing. These options relate to an equal number of underlying shares of Palvella Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIRITSY CHRISTOPHER P

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.19	06/10/2026		A		3,000		(1)	06/10/2036	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)